


WHAT IS CLAIMED IS:

1. A compound of the formula (I):



wherein

R^1 is hydrogen, halogen, hydroxy, amino, $-\text{CHF}_2$, $-\text{CF}_3$, or $-\text{NHSO}_2\text{CH}_3$;

R^2 , R^3 , and R^4 are each independently selected from the group consisting of:
hydrogen;

10 halogen;

$-(\text{C}_1\text{-C}_4)\text{alkyl}$;

$-\text{CF}_3$;

amino;

nitro;

15 $-(\text{CH}_2)_p\text{OR}^{10}$;

$-(\text{CH}_2)_n\text{CN}$;

$-\text{C}(\text{O})\text{NR}^{11}\text{R}^{12}$;

$-\text{C}(\text{O})\text{OR}^{16}$;

$-\text{NHC}(\text{O})\text{R}^{13}$;

20 $-\text{O}(\text{CH}_2)_o\text{Y}$;

$-\text{SCH}_3$;

$-\text{SO}_2\text{R}^{14}$;

N-morpholino;

N-piperazine or N-piperazine substituted with $(\text{C}_1\text{-C}_4)\text{alkyl}$;

25 N-pyrrolidine or N-pyrrolidine substituted with $-(\text{CH}_2)_p\text{OH}$;


-100-

N-1,1-dioxothiomorpholine;

N-[1,4]-diazepinyl;

phenyl or phenyl substituted with $-\text{CF}_3$, nitro, amino, halogen, hydroxy, $(\text{C}_1\text{-C}_4)$ alkyl, $(\text{C}_1\text{-C}_4)$ alkoxy or $-\text{NHSO}_2\text{CH}_3$; and

- 5 piperidine or piperidine substituted on the nitrogen with $-\text{C}(\text{O})(\text{C}_1\text{-C}_4)$ alkyl;
or R^2 and R^3 may, together with the phenyl ring to which they are attached, form a naphthalene (benzo-fused ring) of the structure:



R^5, R^6 and R^8 are hydrogen;

- 10 R^7 and R^9 are each independently hydrogen or hydroxy;
 R^{10} is hydrogen, $(\text{C}_1\text{-C}_4)$ alkyl, $-(\text{CF}_2)_t\text{CHF}_2$, $-(\text{CH}_2)_q\text{NR}^{17}\text{R}^{18}$, $-(\text{CH}_2)_q\text{O}(\text{C}_1\text{-C}_4)$ alkyl),
pyrrolidine, or phenyl;

which pyrrolidine may be optionally substituted on the nitrogen with $\text{C}_1\text{-C}_4$ alkyl.

R^{11} and R^{12} are each independently hydrogen or $(\text{C}_1\text{-C}_4)$ alkyl;

- 15 R^{13} is $(\text{C}_1\text{-C}_4)$ alkyl, cyclopropyl or $-(\text{CH}_2)\text{-OR}^{19}$;
 R^{14} is $(\text{C}_1\text{-C}_4)$ alkyl, $-\text{NR}^{20}\text{R}^{21}$, N-pyrrolidine, phenyl, or $-\text{CF}_3$;
 $\text{R}^{16}, \text{R}^{17}, \text{R}^{18}, \text{R}^{19}, \text{R}^{20}$, and R^{21} are each independently hydrogen or $\text{C}_1\text{-C}_4$ alkyl;
 m is 0, 1, 2, or 3;

n is 0 or 1;

- 20 o is 1, 2 or 3;

p is 0, 1 or 2;

q is 1, 2, or 3;

t is 0 or 1;

Y is morpholine, pyrrolidine, or pyrrolidine substituted on the nitrogen by $(\text{C}_1\text{-C}_4)$ alkyl;

- 25 and the pharmaceutically acceptable salts thereof.

2. The compound according to Claim 1, wherein

R^2 is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, or phenyl;

R^3 is hydrogen or hydroxy;

R^4 is hydrogen, halogen, nitro, cyano, $-CF_3$, $-(CH_2)_pOR^{10}$, or $-SO_2R^{14}$;

p is 0;

R^{10} is $-CHF_2$;

R^{14} is (C_1-C_4) alkyl; $-CF_3$; or $-NR^{20}R^{21}$,

5 and the pharmaceutically acceptable salts thereof.

3. The compound according to **Claim 2** wherein R^4 is nitro;
and the pharmaceutically acceptable salts thereof.

4. The compound according to **Claim 3** wherein R^2 and R^3 are hydrogen.

5. The compound according to **Claim 2** wherein R^2 is hydrogen; R^3 is
10 hydroxy; and R^4 is hydrogen;
and the pharmaceutically acceptable salts thereof.

6. The compound according to **Claim 1**, which is selected from the group
consisting of:

7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-nitrophenyl)-propylamino]-ethyl}-amide,
15 dihydrochloride salt;

7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(4-cyanophenyl)-propylamino]-ethyl}-
amide, dihydrochloride salt;


7-Phenyl-isoquinoline-5-sulfonic acid {2-[3-(2-methyl-4-nitrophenyl)-propylamino]-
ethyl}-amide, dihydrochloride salt;

20 (S)-7-Phenyl-isoquinoline-5-sulfonic acid [2-(3-hydroxy-3-(4-nitrophenyl)-propylamino)-
ethyl]-amide, mesylate salt;

7-Phenyl-isoquinoline-5-sulfonic acid [2-(2,3-dihydroxy-3-(4-nitrophenyl)-propylamino)-
ethyl]-amide isomer 1, dihydrochloride salt; and

7-Phenyl-isoquinoline-5-sulfonic acid [2-(2,3-dihydroxy-3-(4-nitrophenyl)-propylamino)-
25 ethyl]-amide isomer 2, dihydrochloride salt.

7. A compound of the formula:



5 wherein R^1 is hydrogen, halogen, hydroxy, amino, $-\text{CHF}_2$ or $-\text{NHSO}_2\text{CH}_3$;
 R^2 , R^3 , and R^4 are each independently:

hydrogen;

halogen;

-(C1-C4)alkyl;

10 $-\text{CF}_3$;

amino;

nitro;

$-(\text{CH}_2)_p\text{OR}^{10}$;

$-(\text{CH}_2)_n\text{CN}$;

15 $-\text{C}(\text{O})\text{NR}^{11}\text{R}^{12}$;

$-\text{C}(\text{O})\text{OR}^{11}$;

$-\text{NHC}(\text{O})\text{R}^{13}$;

$-\text{O}(\text{CH}_2)_o\text{Y}$;

$-\text{SCH}_3$;

20 $-\text{SO}_2\text{R}^{14}$;

N-morpholino;

N-piperazine or N-piperazine substituted with (C1-C4)alkyl;

N-pyrrolidine or N-pyrrolidine substituted with $-(\text{CH}_2)_p\text{OH}$;

N-1,1-dioxothiomorpholine;


25 N-[1,4]-diazepinyl;

phenyl or phenyl substituted with $-\text{CF}_3$, nitro, amino, halogen, hydroxy, (C1-C4) alkyl, (C1-C4)alkoxy or $-\text{NHSO}_2\text{CH}_3$;

piperidine or piperidine substituted on the nitrogen with $-\text{C}(\text{O})(\text{C1-C4})$ alkyl;

or wherein R^2 and R^3 may together with the phenyl ring of formula I form a naphthalene

5 (benzo-fused ring) of the structure:



R^5 , R^6 and R^8 are hydrogen;

R^7 and R^9 are each independently hydrogen or hydroxy;

R^{10} is hydrogen, (C1-C4)alkyl, $-(\text{CF}_2)_n\text{CHF}_2$, $-(\text{CH}_2)_m\text{NR}^{11}\text{R}^{12}$, $-(\text{CH}_2)_o\text{O}(\text{C1-C4alkyl})$, or

10 phenyl;

R^{11} and R^{12} are each independently hydrogen or (C1-C4)alkyl;

R^{13} is (C1-C4)alkyl, cyclopropyl or $-(\text{CH}_2)_o\text{R}^{11}$;

R^{14} is (C1-C4)alkyl, $-\text{NR}^{11}\text{R}^{12}$, N-pyrrolidine, phenyl, or $-\text{CF}_3$;

m is 0, 1, 2, or 3;

15 n is 0 or 1;

o is 1, 2 or 3;

p is 0, 1 or 2;

Y is morpholine, pyrrolidine or pyrrolidine substituted on the nitrogen by (C1-C4)alkyl; and the pharmaceutically acceptable salts thereof.

20 8. A compound selected from the group consisting of:

7-phenyl-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-difluoromethylphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-aminophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(3-aminophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

25 7-(3-fluorophenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide;

7-(4-methylsulfonamido)- isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide

7-(3-hydroxyphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide; and

7-(4-hydroxyphenyl)-isoquinoline-5-sulfonic acid (2-amino-ethyl)-amide.

9. A pharmaceutical composition comprising a compound of any of **Claims 1-7**, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier, excipient, or diluent.

10. A method for the treatment of susceptible neoplasms comprising
5 administering to a patient in need thereof an effective amount of a compound of any of **Claims 1-7**, or a pharmaceutically acceptable salt thereof.

11. The compound of any of **Claims 1-7**, or a pharmaceutically acceptable salt thereof, for use in therapy.